Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors

NCT04528836 is registered in ClinicalTrials.gov with Navire Pharma Inc., a BridgeBio company as lead sponsor.

NCT NCT04528836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04528836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors
Lead sponsor
Navire Pharma Inc., a BridgeBio company
Phase
Phase 1
Overall status
Terminated
Start date
November 12, 2020
Completion date
July 30, 2024
Enrollment
72 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

tumor, solid